Pharmacokinetics study of BHV-4157
Latest Information Update: 25 Jul 2016
Price :
$35 *
At a glance
- Drugs Troriluzole (Primary)
- Indications Mental disorders
- Focus Adverse reactions
- 20 Jul 2016 According to Biohaven media release, company has begun dosing subjects in this trial to evaluate the safety and pharmacokinectics of BHV-4157 after receiving the FDA clearance on its IND.
- 20 Jul 2016 Status changed from not yet recruiting to recruiting, as per Biohaven media release.
- 07 Jul 2016 New trial record